Intravenous iron in a primary-care clinic

American Journal of Hematology

Volumn 78, Issue 4, 2005, Pages 261-264

  Maslovsky, Igor ^a  

^a BARZILAI MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS GLUCONATE; IRON; IRON DEXTRAN; SODIUM CHLORIDE;

ANAPHYLAXIS; ANEMIA; ARTICLE; BLEEDING; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDICATION; DRUG INFUSION; DRUG SAFETY; ENTERITIS; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; HYPOTENSION; INTESTINE ABSORPTION; IRON DEFICIENCY ANEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; PARESTHESIA; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYMPTOMATOLOGY;

ANEMIA, IRON-DEFICIENCY; FERRIC COMPOUNDS; FERRITINS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE; SUCROSE;

EID: 16344381158     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20271     Document Type: Article

References (9)

1. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004;116(Suppl 7A):44S-49S.
2. Furhoff AK. Anaphylactoid reaction to dextran-a report of 133 cases. Acta Anaesthesiol Scand 1977;21(3):161-167.
3. Fishbane S. Safety in iron management. Am J Kidney Dis 2003; 41(5Suppl):18-26.
4. Bailie GR, Johnson CA, Mason NA. Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis 2000;35(1):1-12.
5. Fishbane S, Wagner J. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. Am J Kidney Dis 2001;37(5):879-883.
6. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22(7):1301-1307.
7. Charytan C, Schwenk MH, Al-Saloum MM, Spinowitz BS. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract 2004;96(2):c63-c66.
8. Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001;16(6):1239-1244.
9. Bastani B, Jain A, Pandurangan G. Incidence of side effects associated with high-dose ferric gluconate in patients with severe chronic renal failure. Nephrology (Carlton) 2003;8(1):8-10.